RVW1 Stock Overview
Provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Physiomics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0025 |
| 52 Week High | UK£0.026 |
| 52 Week Low | UK£0.0005 |
| Beta | 1.69 |
| 11 Month Change | -16.67% |
| 3 Month Change | -72.22% |
| 1 Year Change | -84.38% |
| 33 Year Change | -96.32% |
| 5 Year Change | n/a |
| Change since IPO | -96.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| RVW1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -3.0% |
| 1Y | -84.4% | -9.5% | 4.0% |
Return vs Industry: RVW1 underperformed the German Life Sciences industry which returned -9.5% over the past year.
Return vs Market: RVW1 underperformed the German Market which returned 4% over the past year.
Price Volatility
| RVW1 volatility | |
|---|---|
| RVW1 Average Weekly Movement | 80.6% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: RVW1's share price has been volatile over the past 3 months.
Volatility Over Time: RVW1's weekly volatility has increased from 49% to 81% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 10 | Peter Sargent | www.physiomics.co.uk |
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine.
Physiomics Plc Fundamentals Summary
| RVW1 fundamental statistics | |
|---|---|
| Market cap | €1.75m |
| Earnings (TTM) | -€534.51k |
| Revenue (TTM) | €760.12k |
2.3x
P/S Ratio-3.3x
P/E RatioIs RVW1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVW1 income statement (TTM) | |
|---|---|
| Revenue | UK£641.73k |
| Cost of Revenue | UK£1.14m |
| Gross Profit | -UK£500.86k |
| Other Expenses | -UK£49.61k |
| Earnings | -UK£451.26k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0022 |
| Gross Margin | -78.05% |
| Net Profit Margin | -70.32% |
| Debt/Equity Ratio | 0% |
How did RVW1 perform over the long term?
See historical performance and comparison